HOW COLON CANCER TESTING IS DONE TODAY
In the realm of life-saving tests, colonoscopies have proven their value in the fight to detect the presence of colorectal cancer. Yet, the cost, unpleasantness and discomfort caused by the test leads too many patients to avoid the procedure. In fact, only 50% of patients who should be screened have actually had a colonoscopy.
Whether avoiding the test because of a reluctance to experience discomfort, an unwillingness to take the time, or out of fear, this decision can cost a patient’s life. If detected at Stage I, colorectal cancer has a 90% five-year survival rate. By Stage II, the five-year rate drops to 60% and continues to fall to 10% at Stage IV. A colonoscopy is a valuable tool in detecting early stages of colorectal cancers, but it can’t work if the patient avoids testing.
Clearly a cost-effective alternative, such as a blood test, would be complimentary and drive the correct patients to colonoscopy, reducing false positives from current stool screening tests, and lowering healthcare costs.
New Day Diagnostics, a US-based medical company, asked this question and dove into extensive research to find a solution.
RESEARCH USE ONLY. NOT AVAILABLE FOR SALE IN THE USA.
Coloplex®is a registered trademark of NewDay Diagnostics. ColoPlex is not FDA approved for sale in the U.S.A.